Experimental drug BIIB094 reduced Parkinson's-linked LRRK2 protein by up to 60% in early human trials. The breakthrough targets the genetic cause of the disease affecting 10 million people worldwide.
← News
Science Breakthroughs Science Breakthroughs Knowledge
Experimental drug cuts Parkinson's-linked protein up to 60% in early trial
Up To 60% Protein reduction
10 Million Worldwide People affected
LRRK2 Target gene
10 Million patients affected
60% protein reduction